7.025

3.84% -0.275

Immunitybio Inc (IBRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IBRX? Forum Prognose

Schlusskurs vom Vortag:

$7.30

Offen:

$7.27

24-Stunden-Volumen:

9.34M

Relative Volume:

0.25

Marktkapitalisierung:

$7.25B

Einnahmen:

$113.29M

Nettoeinkommen (Verlust:

$-351.47M

KGV:

-18.02

EPS:

-0.3898

Netto-Cashflow:

$-309.19M

1W Leistung:

+5.41%

1M Leistung:

-19.03%

6M Leistung:

+177.47%

1J Leistung:

+148.06%

1-Tages-Spanne:

$7.00

$7.63

1-Wochen-Bereich:

$6.88

$7.85

52-Wochen-Spanne:

$1.83

$12.43

Immunitybio Inc Stock (IBRX) Company Profile

Firmenname

Immunitybio Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

(844) 696-5235

Adresse

3530 JOHN HOPKINS COURT, SAN DIEGO

Mitarbeiter

691

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

IBRX's Discussions on Twitter

Compare IBRX vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IBRX Immunitybio Inc	7.025	7.54B	113.29M	-351.47M	-309.19M	-0.3898
VRTX Vertex Pharmaceuticals Inc	435.76	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	758.73	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	747.26	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.72	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	164.79	35.01B	606.42M	-1.28B	-997.58M	-6.403

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-12	Fortgesetzt	BTIG Research	Buy
2025-05-20	Hochstufung	Piper Sandler	Neutral → Overweight
2025-03-06	Eingeleitet	H.C. Wainwright	Buy
2025-01-10	Eingeleitet	BTIG Research	Buy
2023-05-12	Herabstufung	Piper Sandler	Overweight → Neutral
2022-08-03	Eingeleitet	Jefferies	Buy

Alle ansehen

Immunitybio Inc Aktie (IBRX) Neueste Nachrichten

09:59 AM

IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com

09:59 AM

08:37 AM

ImmunityBio Addresses FDA Warning on ANKTIVA Promotion - TipRanks

08:37 AM

08:16 AM

ImmunityBio (IBRX) Stock Gains 3% Following FDA Compliance Response on Anktiva Marketing - Blockonomi

08:16 AM

08:13 AM

ImmunityBio submits response to FDA OPDP, removes podcast and strengthens promotional compliance - TradingView

08:13 AM

08:11 AM

ImmunityBio responds to FDA promotional compliance concerns By Investing.com - Investing.com India

08:11 AM

08:03 AM

ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan

08:03 AM

07:58 AM

ImmunityBio (IBRX) Stock Climbs 3% After Firing Back at FDA Over Anktiva Ad Concerns - CoinCentral

07:58 AM

07:32 AM

Immunitybio Addresses FDA Correspondence And Reaffirms Commitment To Advertising Compliance - TradingView

07:32 AM

07:30 AM

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance - businesswire.com

07:30 AM

03:49 AM

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

03:49 AM

Apr 05, 2026

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald

Apr 05, 2026

IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits

Apr 05, 2026

Securing Non-Dilutive Funding to Support Immunotherapy Platform Growth – ImmunityBio - Oncodaily

Apr 05, 2026

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer

Apr 05, 2026

CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Downgrade) - Seeking Alpha

Apr 05, 2026

Apr 04, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 04, 2026

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - globenewswire.com

Apr 04, 2026

ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up - TipRanks

Apr 04, 2026

IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Morningstar

Apr 04, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Apr 04, 2026

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - Sahm

Apr 04, 2026

Investors with Substantial Losses in ImmunityBio (IBRX) Have Opportunity to Lead Class Action Lawsuit - National Today

Apr 04, 2026

Apr 03, 2026

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

Apr 03, 2026

IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire

Apr 03, 2026

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire

Apr 03, 2026

Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - Carroll County Mirror-Democrat

Apr 03, 2026

When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio - Medical Marketing and Media

Apr 03, 2026

NYSE: PINS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Pinterest, Inc. - GlobeNewswire Inc.

Apr 03, 2026